# Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

> **NCT03646461** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Diego** · enrollment: 5 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Ibrutinib 560mg PO daily (Imbruvica)
- **DRUG:** Cetuximab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03646461
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-17
- **Primary completion:** 2025-12-11
- **Final completion:** 2025-12-30
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03646461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03646461, "Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03646461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*